Atomic AI

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. Diana Spencer spoke to Raphael Townshend, PhD, Founder and CEO of Atomic AI, about the advantages of combining two such exciting technologies. Artificial Intelligence (AI) has been enthusiastically adopted by the drug discovery sector as a tool for […]

New kids on the block, Atomic AI, recently closed a $35 million series A financing. DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models.  DS: Congratulations on closing a […]